AN2 Therapeutics, Inc.
ANTX
$1.10
-$0.03-2.66%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 19.84% | -7.86% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 34.04% | -26.88% | |||
| Operating Income | -34.04% | 26.88% | |||
| Income Before Tax | -41.57% | 40.99% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -41.57% | 40.99% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -41.57% | 40.99% | |||
| EBIT | -34.04% | 26.88% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -40.76% | 41.08% | |||
| Normalized Basic EPS | -40.63% | 28.41% | |||
| EPS Diluted | -40.76% | 41.08% | |||
| Normalized Diluted EPS | -40.63% | 28.41% | |||
| Average Basic Shares Outstanding | 0.57% | 0.14% | |||
| Average Diluted Shares Outstanding | 0.57% | 0.14% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||